| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698524 | Clinical Oncology | 2012 | 6 Pages |
Abstract
The regimen of weekly single agent paclitaxel is feasible in patients with locally advanced breast cancer with acceptable toxicity. It resulted in a pathological response rate that was comparable with other regimens in this group of advanced stage patients. Considering the efficacy and low toxicity of this regimen, it is worth exploring in larger studies.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
S. Gupta, R. Bharath, T. Shet, S.B. Desai, V.M. Patil, A. Bakshi, V. Parmar, R.A. Badwe,